Stephanie Sells
Primary Care · Halls, TNNPI 1770908998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 24.7% of the total.
Across 221 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$829
- AstraZeneca$451
- Kowa Pharmaceuticals America, Inc.$386
- Bayer$273
- Otsuka America Pharmaceutical, Inc.$261
- plus $974 from 13 others
What the payments were for
- Food & beverage$4,215100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,042 |
| Novo Nordisk | 53 | $829 |
| AstraZeneca | 13 | $451 |
| Kowa Pharmaceuticals America, Inc. | 17 | $386 |
| Bayer | 15 | $273 |
| Otsuka America Pharmaceutical, Inc. | 15 | $261 |
| Lilly USA, LLC | 11 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $171 |
| Lundbeck LLC | 4 | $113 |
| Boehringer Ingelheim | 5 | $104 |
| Abbott | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Amgen(2 entities) | 4 | $61 |
| Pfizer | 3 | $57 |
| GSK | 2 | $39 |
| Johnson & Johnson | 1 | $27 |
| Mylan Specialty L.p. | 1 | $15 |
| Insulet Corporation | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,215 in reported general payments places this provider in the 85th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $92,783 |
| JardianceEmpagliflozin | 96 | $86,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $52,799 |
| MounjaroTirzepatide | 31 | $41,616 |
| JanuviaSitagliptin Phosphate | 36 | $35,736 |
| EliquisApixaban | 20 | $27,468 |
| VraylarCariprazine Hcl | 19 | $27,323 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $19,472 |
| TrintellixVortioxetine Hydrobromide | 22 | $13,772 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,423 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $8,893 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,911 |
| Aripiprazole | 15 | $6,896 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $5,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 125 | $5,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $104 | $95,489115 claims |
| Novo NordiskOzempic | $829 | $92,78376 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $39 | $60,71082 claims |
| Lilly USA, LLCMounjaro | $182 | $41,61631 claims |
| PfizerEliquis | $57 | $27,46820 claims |
| AbbVieVraylar | $1,042 | $27,32319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $90 | $18,84835 claims |
| AstraZenecaBreztri Aerosphere | $451 | $10,42315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 primary care providers in Tennessee.
Other primary care in Halls
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
- Katie JohnsonClarksville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.